Swiss Evaluation Registry for Pediatric Infective Endocarditis (SERPIE) - Risk factors for complications in children and adolescents with infective endocarditis



Schuler Stefanie Katharina, Crisinel Pierre Alex, Joye Raphael, Rohr Marie, Bressieux-Degueldre Sabrina, Glöckler Martin, Paioni Paolo, K.A. Agyeman Philipp, Knirsch Walter

| PII:           | S0167-5273(22)01684-9                        |
|----------------|--|
| DOI:           | https://doi.org/10.1016/j.ijcard.2022.10.173 |
| Reference:     | IJCA 30686                                   |
| To appear in:  | International Journal of Cardiology          |
| Received date: | 2 August 2022                                |
| Revised date:  | 27 October 2022                              |
| Accepted date: | 30 October 2022                              |

Please cite this article as: S.S. Katharina, C.P. Alex, J. Raphael, et al., Swiss Evaluation Registry for Pediatric Infective Endocarditis (SERPIE) - Risk factors for complications in children and adolescents with infective endocarditis, *International Journal of Cardiology* (2022), https://doi.org/10.1016/j.ijcard.2022.10.173

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier B.V.

## Swiss Evaluation Registry for Pediatric Infective Endocarditis (SERPIE) -

## Risk factors for complications in children and adolescents with infective

## endocarditis

Schuler Stefanie Katharina<sup>1 2</sup>, Crisinel Pierre Alex<sup>3</sup>, Joye Raphael<sup>4</sup>, Rohr Marie<sup>5</sup>, Bressieux-Degueldre Sabrina<sup>6</sup>, Glöckler Martin<sup>7</sup>, Paioni Paolo<sup>8</sup>, Agyeman Philipp K. A.<sup>9</sup>, Knirsch Walter<sup>1 2</sup>

#### Corresponding author and contact details

Prof. Dr. Walter Knirsch

University Children's Hospital Zurich, Pediatric Heart Center, Pediatric Cardiology

Steinwiesstrasse 75

CH-8032 Zurich, Switzerland

Email: Walter.Knirsch@kispi.uzh.ch

### **Conflicts of interest**

The authors have no conflicts of inte. st to disclose.

## Abstract

<sup>&</sup>lt;sup>1</sup> Pediatric Cardiology, Peoultric Heart Center, University Children's Hospital Zurich, University of Zurich, Switzerland\*; Steirw.esstrasse 75, CH-8032 Zurich, Switzerland

<sup>&</sup>lt;sup>2</sup> Children's Research Center, University Children's Hospital Zurich, University of Zurich, Switzerland\*; Steinwiesstrasse 75, CH-8032 Zurich, Switzerland

<sup>&</sup>lt;sup>3</sup> Pediatric Infectious Diseases, Service of Pediatrics, Department Woman-Mother-Child, Lausanne University Hospital and University of Lausanne, Switzerland\*; Route du Bugnon 46, CH-1011 Lausanne, Switzerland

<sup>&</sup>lt;sup>4</sup> Pediatric Cardiology Unit, Children's University Hospital, Geneva, Switzerland\*; Rue Willy-Donzé 6, CH-1205 Geneva, Switzerland

<sup>&</sup>lt;sup>5</sup>Pediatric Infectious Diseases Unit, Department of Pediatrics, University Hospital Geneva, University of Geneva, Switzerland\*; Rue Willy-Donzé 6, CH-1205 Geneva, Switzerland

<sup>6</sup> Pediatric Cardiology Unit, Service of Pediatrics, Department Woman-Mother-Child, Lausanne University Hospital and University of Lausanne, Switzerland\*; Route du Bugnon 46, CH-1011 Lausanne, Switzerland

<sup>7</sup> Department of Congenital Heart Diseases, Inselspital, Bern University Hospital, University of Bern, Switzerland\*; Freiburgstrasse 15, CH-3010 Bern, Switzerland

<sup>8</sup> Division of Infectious Diseases and Hospital Epidemiology, University Children's Hospital Zurich, University of Zurich, Switzerland\*; Steinwiesstrasse 75, CH-8032 Zurich, Switzerland

<sup>9</sup> Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland\*; Freiburgstrasse 15, CH-3010 Bern, Switzerland

<sup>\*</sup> This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation.

<u>Background:</u> Infective endocarditis (IE) in pediatric patients is a severe cardiac disease and its actual epidemiology and clinical outcome in Switzerland is scarcely studied.

<u>Methods:</u> Retrospective nationwide multicenter data analysis of pediatric IE in children (<18 years) between 2011 and 2020.

Results: 69 patients were treated for definite (40/69;58%) or possible IE (29/69;42%). 61% (42/69) were male. Diagnosis was made at median 6.4 years (IQR 0.8-12.6) of age with 19 patients (28%) during the first year of life. 84% (58/69) had congenital heart defects. IE was located on pulmonary (25/69;35%), mitral (10/69;14%), tricuspid (8/69;12%) and aortic valve (6/69;9%), and rarely on ventricular septal defect (VSD;4/69;6%) and atrial septal defect (ASD;1/62;1%). In 22% (16/69) localization was unknown. 70% (48/69) had postoperative IE, with provide the material involved in 60% (29/48; right ventricular to pulmonary artery conduit (24), VSD (4), ASD (1)). Causative organisms were mostly *Staphylococci spp.* (25;36%) including *Staph; loco ccus aureus* (19;28%), and *Streptococci spp.* (13;19%). 51% (35/69) suffered from revere complications including congestive heart failure (16;23%), sepsis (17;25%) and embc' sm (19;28%). *Staphylococcus aureus* was found as a predictor of severe complications in unival relations in unival relations analysis (p=0.02 and p=0.033). In 46% (32/69) cardiac surgery was performed 7.7% (5/69) died.

<u>Conclusions</u>: IE in childhood remains a severe cardiac disease with relevant mortality. The high morbidity and high rate of complications is associated with *Staphylococcus aureus* infections. Congenital heart defects act as a nink factor for IE, in particular the high number of cases associated with prosthetic pulmonary valve needs further evaluation and therapeutic alternatives.

Key words: Infective enderarditis, child, congenital heart disease, complication, Staphylococcus aureus

#### 1. Introduction

Infective endocarditis (IE) in childhood is associated with high morbidity and mortality.<sup>1–3</sup> The incidence of pediatric IE is reported with 0.43-0.84/100'000 children per year,<sup>4–7</sup> with increasing trend in recent years.<sup>8–11</sup>

In developed countries, congenital heart disease (CHD) plays the dominant role as predisposing factor for pediatric IE.<sup>4,6,7,12–14</sup> This includes children with native and prosthetic valves affected.<sup>1,10,15</sup> Nowadays, prosthetic valve IE in children with CHD are associated with severe clinical course leading to complications.<sup>13,15</sup> From the clinical point of view, early determine tion of risk factors contributing to complications is essential.

Due to the limited cases of pediatric IE, multicenter surveys such as hation-wide registries are needed. In Switzerland, two single-center studies on pediatric infective undocarditis have been published.<sup>16,17</sup> So far, nation-wide data are missing. Therefore, the <u>Swins</u> <u>valuation</u> <u>Registry for</u> <u>Pediatric</u> <u>Infective</u> <u>Endocarditis</u> (SERPIE) was founded in 2020 with the run ose to build up a prospective data collection of the microbiological spectrum, diagnostics. predisensing risk factors, clinical course, complications, therapy, and outcome of pediatric IE in Switterland. To optimally prepare for the launch of the SERPIE, we conducted the analysis baced on national retrospective data on pediatric IE presented here.

As it seems that especially childre, with CHD experience more severe courses of IE,<sup>13,15</sup> and in the last two studies conducted in Chitzerland, mainly children with CHD were found to be at risk for IE, especially when foreign matric, was used for treatment of the CHD,<sup>16,17</sup> the *SERPIE* study also aimed to analyze factors associated with complicated clinical courses.

#### 2. Methods

#### 2.1. Study design

In 2020, a network of pediatric cardiologist and pediatric infectious disease specialists was built up on behalf of the "Verein Kinderherzforschung Schweiz" (Association of Children's Heart Research Switzerland) and with the consent of the participating pediatric cardiac surgeons and the Swiss Society of Pediatric Cardiology. In Switzerland, the pediatric cardiac surgery program concentrates on four main tertiary pediatric heart centers performing invasive pediatric cardiac procedures including cardiac surgery as well as catheter-based cardiac interventions. T, is includes the tertiary Pediatric University Children's Hospital in Berne, Geneva, Lausanne, and Zu ich.

This study was designed as a retrospective nationwide multicenter analysis including cases of pediatric infective endocarditis in children under 18 years or ane treated in Switzerland between 2011 and 2020. After ethical committee approval was achieved CASEC Number 2021-00862), patients were searched in the local medical data bases in Fault of the main four pediatric cardiac center, since our preliminary discussion revealed that all cases treated for IE have been doubtfully treated within these four main centers or in direct cooperation with them.

### 2.2. Patients and variables

Patients' consent was given by prinary (general) consent for retrospective data analysis, or a secondary consent was obtained in written form for study participation. Only patients fulfilling the modified Duke criteria for lefinie or possible IE were included.<sup>18</sup> Patients' data were recorded in an encoded way into REDCape. We collected data analysis regarding diagnostic, microbiological, clinical and therapeutic variables, and outcomes. To calculate the incidence of IE in Switzerland, national data from the Federal Statistical Office on children under 18 years of age living in Switzerland were used (https://www.bfs.admin.ch/bfs/de/home/stastiken/bevoelkerung/stand-

entwicklung/bevoelkerung.assetdetail.18404679.html)

Based on the AHA guideline for the antibiotic endocarditis prophylaxis from 2007,<sup>19</sup> which were adopted in 2008 for Switzerland,<sup>20</sup> all patients were classified into a "predisposed" or "non-predisposed" group, i.e. antibiotic prophylaxis was recommended or not during high-risk interventions. This includes patients with prosthetic valve, patients with previous IE, patients with unrepaired cyanotic CHD including palliative shunts and conduits or patients with any type of CHD repaired with a prosthetic material within 6 months after procedure or lifelong if residual shunt remains.<sup>19</sup> The first day

of intravenous antibiotic therapy was defined as the day of diagnosis of IE. Postoperative IE was diagnosed if the patient underwent previous cardiac surgery or catheter intervention. Severe complications were defined as sepsis, embolism or severe congestive heart failure.<sup>21</sup> Severe congestive heart failure was defined as impaired ventricular myocardial function determined by echocardiography, hemodynamic instability, and clinical signs of congestive heart failure such as hepatomegaly, pulmonary oedema, or cardiac-related renal failure. Patients were classified into "acute" versus "subacute" IE accordingly to their clinical course. IE was defined as "acute" if severe complications occurred and/or early surgical intervention during antibiotic treatment was performed. Predisposing factors for IE were known CHD, prior history of IE, control were like immunodeficiency, genetic or oncologic comorbidities, and temporary or permanent ir serted central venous catheter line before diagnosis of IE.

#### 2.3. Statistics

Statistical analysis was performed using STATA `ersion 16 (StataCorp, Texas, United States of America). Continuous variables are described on the ending and interquartile ranges (IQRs), categorial variables as counts and frequencies. Yearly and median incidence was calculated using the yearly respective median numbers of patients tracted for IE and children under 18 years of age living in Switzerland. Intergroup comparison was done using Kruskal-Wallis test for continuous variables and chi-square test or Fisher's exact test for categorial variables. A multivariate logistic regression analysis with adjustment for age, co-monimizing and gender was performed for each potential predictor identified in the univariate analyses (with P-value  $\leq 0.05$ ) and adjusted odds ratio (OR) and 95% confidence interval (CI) we calculated. All tests were 2-tailed, and a P-value  $\leq 0.05$  was considered statistically significant.

#### 3. Results

#### 3.1. Patients

The medical data base research revealed a total number of 95 patients fulfilling inclusion criteria. 24 patients were treated as part of humanitarian project and lost to follow up. For 48 patients a primary consent was available. Of the remaining 23 patients, 2 refused consent so that finally a total of 69 patients were included in the study.

Patients fulfilled the modified Duke criteria for definite IE and for possible IE in 58% (40/69) and 42% (29/69) of cases, respectively. IE was diagnosed at a median age of 6... vears (IQR 0.8-12.6) with 28% (19/69) during the first year of life. 61% (42/69) were male pations. The median incidence of IE was 0.33 (IQR 0.27-0.54) patients per year and 100'000 children. uncler 18 years of age living in Switzerland.

#### 3.2. Predisposing factors for IE

Fifty-eight of the 69 (84%) patients had a accumented congenital heart disease (Table 1) as a predisposing factor, of those 55% were cyanctic CHD (32/58). 17% were unrepaired CHD (10/58), while 83% (48/58) patients had postoperative IE. At least 60% (29/48) of the patients with postoperative IE were proven to be accoriated with prosthetic material. Postoperative IE was diagnosed at a median of 1.5 yea's (ICR 0.4-8.8) after cardiac intervention. Ten of 48 (21%) patients with postoperative IE had an carly postoperative IE within 30 days after cardiac procedure. Two of the 69 (3%) patients already stiffered from IE before. According to the guidelines for antibiotic prophylaxis in Switzerland, 61% (42/69) of the patients were at high risk for IE, where antibiotic prophylaxis is recommended.<sup>20</sup> In only 2 cases prior dental treatment was documented, these children received antibiotic prophylaxis.

In the group of patients with CHD, the following additional risk factors were found: central venous catheter (n=6), genetic syndromes (n=5), oncologic comorbidities (n=3), primary immunodeficiency (n=2) and previous IE (n=2). Two patients with CHD were born preterm with persistent ductus arteriosus (PDA) and IE occurring early after birth.

In 29 of 69 (42%) a possible source for transient bacteremia was identified, mostly skin or soft tissue infections (n=10), or central venous catheters (n=9; see Table A in appendix).

#### 3.3. Localization of IE

IE affected valves in pulmonary (25/69; 35%), mitral (10/69; 14%), tricuspid (8/69; 12%) and aortic position (6/69; 9%), VSD (4/69; 6%), ASD II (1/69; 1%) and PDA (2/69; 3%). Multiple infections occurred in 2 of 69 (3%) patients, with one patient with IE affecting tricuspid valve and a VSD-patch, and one patient with an unrepaired AVSD with infected mitral and tricuspid valve and infected PDA. Localization was undetermined in 16 of 69 (22%). In total, isolated right sided IE occurred in 31 of 69 (45%), isolated left sided IE in 15 of 69 (22%).

Prosthetic valve associated IE affected only the right ventricular to rulmonary artery (RV-PA) conduit in 24 of 48 (41%) postoperative IE. The type of RV-PA conduit a new poincided in 18 of 24 (75%) predominately the Contegra valve conduit (Medtronic Co., Mürchenbuchsee. Switzerland), in 4 of 24 (17%) the Melody valve (Medtronic Co., Münchenbuchsee, Switzerland), in 1 of 24 (4%) a homograft, and in 1 of 24 (4%) a Shelhigh-Conduit (Shelhigh Inc., New Tellsey, USA). Of note, all IE localized in a VSD or ASD were associated with foreign material stor as VSD patches (n=3) including a loose patch VSD, or Amplatzer (Abbott Medical Co., Baar Switzerland) septal occluder for VSD (n=1) or ASD (n=1) closure. All 16 of 69 (22%) patients with undetermined localization of IE had CHD, the majority (13/16; 81%) had postoperative IE with implanted foreign material in 12 of 13 (92%) patients. Implanted foreign material in these patients included VSD patch (n=10), RV-PA (n=7, Contegra valve (n=5), Melody valve (n=2)), prosthatic mitral valve, ASD patch or other (each n=1).

### 3.4. Imaging findings

In all patients (69/69; 100°) transthoracic echo (TTE) was performed for diagnosis, 29% (20/69) additionally underwent transesophageal echo (TEE). Positive echocardiographic findings according to the Duke criteria were found in 42 of 69 (61%) patients including vegetation (38/42; 90%), new valve regurgitation (8/42; 19%), new dehiscence of prosthesis (2/42; 5%), and paravalvular abscess (2/42; 5%; multiple findings included). In 10 of 69 patients (14%) only pathologic echo findings not fulfilling the Duke criteria were found, in 17 of 69 patients (25%) echo was negative. Therefore, the positive rate according to Duke was 55% (38/69) in TTE and 60% (12/20) in TEE. With all pathologic findings included the positive rate was 71% (49/69) in TTE and 70% (14/20) in TEE.

One patient with negative echo presented the picture of IE on the pulmonary valve in PET-CT that was performed to ensure diagnosis.

### 3.5. Microbiological findings

Pathogens determined in blood culture are listed in

Table 2. Blood culture negative IE was found in 8 of 69 (12%) patients. In 3 of 8 (38%) patients the causative pathogen could be determined by positive serology for *Coxiella burnetii* (n=1), positive culture for *coagulase negative Staphylococcus* on an explanted valve (n=1) and positive culture for *Nocardia* on tracheal secretion in a patient with chronic granulomatous disease (n=1). No pathogen could be determined by any technique in 5 of 69 (7%) patients, all of them meeting the Duke criteria for *possible* IE.

Associated bacterial findings with the same pathogen determined in 2003 culture were found in 18% (11/61) with positive cultures of cerebrospinal fluid (n=3), explanaed valve material (n=7), wound swab of necrotizing fasciitis (n=1) and urine (n=1).

3.6. Clinical findings and complications

Clinical findings are shown in

Table 3. The diagnosis was made at median 6.5 days (IQR 3-14) after first symptom, which most often was fever (59/69; 86%). 58% (40/69) of the patients were diagnosed with acute IE.

One of the 69 patients (1%) did have no symptoms. This was a 3-month-old boy with complete congenital AV-blockage after implantation of a pacemaker with ventricular pacing leads. At echocardiographic follow-up 30 days after intervention, he presented with new tricuspid valve stenosis and pacemaker leads suspicious of infection. *Coagulase negative Staphylococcus* was identified on the replaced tricuspid valve.

Infectious diseases associated with the manifestation of IE were found in 20% (14/69) of patients, most often pneumonia (11/69; 16%) and meningitis (3/69; 4%; con Table B in appendix). Many children already presented with multiple infectious foci at the train of hospitalization, so it is not possible to say with certainty which one appeared first. 3 of the 69 patients (4%) suffered severe invasive infections: one immunocompetent patient had invasive Candida infection with pneumonia, a patient with hypogammaglobulinemia had invasive *Pemophilus influenzae* type B infection with epiglottitis, and one patient with chronic granulomatous disease suffered from systemic nocardiosis with septic shock and acute respiratory distrems yndrome (ARDS).

## 3.7. Clinical course, therapy ard citcome

Information on severe complicatio. s, therapy and outcome are listed in

Table 3 (more detailed information in Table C in appendix). Intravenous specific antibiotic therapy (69/69; 100%) was performed for at least 4 weeks according to international guidelines.<sup>22</sup> Pathogens found in patients who required surgical intervention (

Table 3) were *Staphylococcus spp.* (15/32; 47%), *Streptococcus spp.* (5/32; 16%), HACEK (3/32; 9%), Enterococcus (3/32; 9%) and other (4/32; 13%). Severe complications occurred in 52% (

Table 3), 7% of patients (5/69) died.

A 2-month-old preterm infant (gestational age 33 6/7) died within 10 days after valve replacement due to severe congenital mitral valve regurgitation. He suffered IE of unknown localization and died of *coagulase-negative staphylococcal* sepsis with severe heart failure and cardiogenic shock.

A 17-year-old patient with DiGeorge syndrome and low native T cells, postoperative pulmonary atresia with implantation of a Melody valve died of pulmonary valve IE positive for *Staphylococcus aureus*. He suffered fulminant sepsis with multi-organ failure and DIC.

Another 4-month-old with HLSH died three months after cardiac surgery due to a *coagulase-negative Staphylococcus* IE on the tricuspid valve. Although he underwent surgical intervention with valve repair because of severe tricuspid regurgitation, he died of sept is with heart failure and severe hypoxemia.

A 4-year-old child died after aortic valve IE and system a nocardiosis with septic shock and multiple organ failure. After IE diagnosis, he was diagnosed with previously unknown chronic granulomatous disease.

A 6-month-old patient with AVSD repair these months prior to diagnosis of IE at unknown location died of enterococcal sepsis following necrotizing enterocolitis with ARDS and renal failure.

In our study period one patient ha. a relapse of IE.

#### 3.8. Predictors for IE with complications

In univariate analysis, *St. phylococcus aureus*-infections was found as a predictor of severe complications, whereas age, CHD, prosthetic material and CRP levels at admission were not associated with complicated clinical courses (Table 4). In the multivariate analysis adjusted for age, gender and risk factors, *Staphylococcus aureus*-infection was also found as a predictor of severe complications (p=0.033, OR 4.079, 95%-CI 1.117-14.89).

#### 4. Discussion

This study constitutes the first nationwide analysis of pediatric infective endocarditis in Switzerland and based on the findings of 69 patients treated for IE between 2011 and 2020. The incidence for pediatric IE of 0.33 per 100'000 per year was comparable to prior published single center cohorts.<sup>17</sup> In our

cohort, more than half of the patients suffered from severe complications leading to a high demand for surgical treatment in 46%.

The most frequent pathogen causing IE in our study population was *S. aureus* (26%) followed by *Viridans Streptococci* (14%). The impact of both pathogen is well-known since decades as the causative pathogen for pediatric IE.<sup>4,6,7,23,24</sup> In recent decades, however, there has been a shift towards an increasing number of *S. aureus* associated IE.<sup>11</sup> A contributing factor is that *Viridans Streptococci* are most common in patients with underlying CHD, whereas *Staphylococcus* is increasingly found in the absence of predisposing CHD.<sup>6,25,26</sup> The latter group seems to have increased in the last decades.<sup>27</sup> Overall, the increasing prevalence of more "aggressive" pathogens seem to change the clinical picture with frequent complications and cave re clinical course.

The overall mortality in our study population was 7% and is c<sup>-</sup>mparable with recently published results for pediatric IE, ranging between 3% and 24%.<sup>3,4,25,2,,28-3,6,7,11-15,24</sup> Despite the mortality, high morbidity of IE may be determined by the occurrence of major complications in more than half (51%) of our study population. All our patients dying from peulatric IE suffered from severe complications. In contrast to other studies investigating severe courses of pediatric IE, but focusing more on embolic complications or death,<sup>6,14,28</sup> we analyzed three main complications including sepsis, embolism, and severe congestive heart failure. Therefore the high number of complicated courses in our study population may be overestimated.

In our study population, *S. aureus* was found as a risk factor for severe complicative course (Table 4), which has been described by other groups as risk factor not only for complicated courses, but also for death.<sup>6,28,30</sup> However, we could not find an association between *coagulase-negative Staphylococcus* (CoNS) infection and severe complications, although CoNS were identified as the causative agent in two of the five patients dying due to postoperative IE. Other studies already described CoNS as a risk factor for severe complications and death in pediatric IE with prosthetic valves<sup>31</sup> as well as for the adult population.<sup>32</sup>

Nearly half of our study population (47%) needed early surgical intervention for IE during antibiotic treatment, which is comparable with literature ranging from 30 to 60%.<sup>3,4,7,12,13,23,25,28,30,33</sup> In 47% of our patients requiring surgical therapy (15/32), *Staphylococcus* were found as causative organisms. Other studies already found *Staphylococcus* infections more frequent in patients who require surgical treatment.<sup>28,31</sup> Additionally, these patients seem to need earlier surgical treatment.<sup>23,31</sup> In our study population, 75% of all surgically treated patients required early surgery during antibiotic treatment.

This proportion is difficult to compare with the literature, as many surgical publications defined early surgery as surgical intervention within 3 to 7 days of diagnosis.<sup>23,28,34</sup>

For the adult population with IE, CRP levels at admission were found as predictive risk factor for inhospital mortality, severe complications such as embolism or congestive heart failure, and need for early surgical intervention.<sup>35–37</sup> Although CRP levels at admission in patients with severe complications were twice as high compared to patients without severe complications, we could not determine CRP levels as a predictor of severe complications (Table 4).

In our study population 84% had CHD (Table 1), most of them were cyanotic (32/58; 55%) and acquired postoperative IE (48/58, 83%) with a high rate of prosthetic material infections (29/48; 60%). Other studies found CHD as the major predisposing factor for  $\Gamma_{-,}^{3-12-4,25,28}$  with increasing numbers of CHD associated IE during the last decades.<sup>10</sup> Especially complex and cyanotic CHD seem to be at risk.<sup>4,10,13,28,29</sup> Also the incidence of postoperative IE was found to be increasing<sup>11</sup> with higher risk for IE within the first months postoperative as well as after use of foreign material.<sup>10,13</sup> The high percentage of patients with CHD could also be due to the fact that there is a higher level of suspicion for IE in patients with a predisposition. This is especielly required for diagnosis in children with unspecific clinical symptoms.<sup>38</sup>

The RV-PA conduit was the most frequer t1 calization for pediatric IE overall (35%). Pulmonary valve in pediatric IE is reported in the differature between 17 and 38 %, mostly in association with postoperative IE in children with C14D.<sup>3,12,25,30</sup> Overall, RV-PA infections seemed to have increased in recent years. A systematic review describes the incidence of IE after Melody valve implantation between 3-14%.<sup>1</sup> Another sistematic review found the incidence of IE in adult populations higher in bovine jugular vein grafts (BJV) than other types of RV-PA conduits (5.4% vs. 1.2%, p<0.0001), but no difference was found between surgical (Contegra) or catheter-based implanted RV-PA BJV grafts (Melody). The BJV grafts may be more sensitive due to their specific tissue characteristics predisposing to bacterial adhesion, while the implantation method itself (surgery vs. catheter-based) does not alter the risk for IE, as we had pediatric cases in both.<sup>39</sup>

As other foreign material associated IE, we found 4 patients after VSD respectively one patient after ASD closure, either due to infected VSD patches (n=3) or infected Amplatzer devices (n=2). This type of pediatric IE after VSD or ASD correction using Amplatzer devices has rarely been described in case reports.<sup>2</sup> Jalal et al. found incomplete endothelialization in two thirds of Amplatzer device related IE more than 6 months after implantation. This delayed or incomplete endothelialization increases the

risk of delayed infection so that the authors discussed a prolongation of postoperative AB prophylaxis.<sup>40</sup>

Interestingly, neither CHD nor foreign material was found to be a risk factor for severe courses in our study. This is in contrast to the findings of various other studies, which state that CHD, especially severe or cyanotic CHD, is associated with increased mortality.<sup>13,15,29</sup> Furthermore, prosthetic valves have already been described as a risk factor for death.<sup>31</sup>

Comparable to some recent findings that 28 to 33% of children with IE have septic embolism,<sup>3,4,41</sup> 28% of our study population suffered this severe complication. On the contrary, our rates of thromboembolic complications are higher than other reported numbers of 6% and 15%.<sup>6,14</sup> These lower values could be explained by the fact that in both studies only stroke was considered as a thromboembolic complication, whereas in our study thromboembolic complications beyond the central nervous system were also included. However, a long-ter. Canadian study conducted over a 30-year period found that 40% of children with IE had thromboembolic complications in the first decade of this century, with thromboembolic events associated with age over 3 years.<sup>28</sup> As the median age of the patients in our study population were younger than one year, this could partly explain the different findings. Furthermore, an American study of neurological complications in pediatric infective endocarditis found that more than, one fifth of the patients with neurological complications were asymptomatic and only found incide. and you complications. This could lead to an underestimation of the events.

The rate of congestive heart failure in our study population (23%) as a complication of IE is higher than the 12 to 15% reported.<sup>4,14</sup> The comparison with both studies should be taken with caution, as neither study describes a definition of heart failure.

Right-sided infections occurred in almost half of the patients (45%), which is comparable to results from Belgium.<sup>12</sup> In a multicenter registry in Spain, right-sided infections were found to be more common in children with CHD, with infections of the RV-PA being most frequent.<sup>3</sup> Additionally, IE in pulmonary valve position has been found to increase in patients with complex CHD.<sup>1,12,25</sup> On the other hand, several other studies presented smaller numbers of right-sided infections (15-33%).<sup>3,4,7,14</sup> In these studies either a lower percentage of CHD was found to be a predisposing risk factor<sup>3,4,7</sup> or the reported CHD were less complex and mostly involved VSD.<sup>14</sup>

In 16 of our patients (22%) localization was unknown, all had CHD pre-diagnosed, and of them 81% (13/16) had postoperative IE with implanted foreign material in 75% (12/16). In other studies, no localization of IE was found in 14-33% of the patients,<sup>4,7,13,33</sup> most of them having inconclusive echo due to CHD with complex anatomy or the use of prosthetic material.<sup>7,33</sup> A study on IE in adults found no vegetation on echo after implantation of pulmonary valves in up to 50% of cases, even after TOE.<sup>43</sup> Thus, an estimated number of unknown locations can be assumed, with the RV-PA conduits probably being affected even more frequently.

In 2015 the European Society of Cardiology (ESC) included 18F-fluorodeoxyglucose (18F-FDG) PET-CT as a diagnostic criteria for infective endocarditis as an "important supplementary method for patients with suspected IE and diagnostic difficulties",<sup>21</sup> for example in patients with suspected prosthetic valve IE.<sup>1</sup> In one of our patients definite diagnosis could be made by a positive PET-CT after inconclusive echo findings.

The main limitations of this study are the retrospective approach and low statistical power due to the sample size. Therefore, further studies with larger numbers of patients are needed to identify risk factors. Although the study was conducted a tionwide with the participation of the four major tertiary cardiac centers, 69 patients could be included in the study over the last ten years. As only tertiary hospitals participated in the study, the end of the study over the last ten years. To avoid this bias, the smaller pediatric cardiology centers in Switzerland were contacted before the start of the study, showing that the patience with IE were all treated in collaboration with the large centers. Nevertheless, some patient's end of have been included in the study, for example because they were treated by adult specialists. It would also be interesting to compare our pediatric data with data from adults in Switzerland. Unfortunately, there does not exist such comparable data yet. Also, this is the first study to look at the combination of severe complications including sepsis, congestive heart failure and embolism, which makes it difficult to compare our findings with other studies and the comparisons done should be taken with caution.

#### 5. Conclusion

IE is still a severe cardiac disease in childhood with relevant mortality. It is also associated with relevant morbidity, including high rates of severe complications associated with *Staphylococcus aureus* infections and often involvement of surgical intervention. Congenital heart diseases represent

a risk factor for IE, in particular the high number of cases associated with prosthetic pulmonary valve needs further evaluation and therapeutic alternatives.

#### 6. Acknowledgement

The "Verein Kinderherzforschung Schweiz" (Association of Children's Heart Research Switzerland) supported the project. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

#### 7. References

- Dixon, G. & Christov, G. Infective endocarditis in childrer . An update. *Curr. Opin. Infect. Dis.* 30, 257–267 (2017).
- Knirsch, W. & Nadal, D. Infective endocarditis in concernital heart disease. *Eur. J. Pediatr.* 170, 1111–1127 (2011).
- Vicent, L. *et al.* Infective endocarditis in children and adolescents: a different profile with clinical implications. *Pediatr. Res.* 1–7 (2022) dr i:10.1038/s41390-022-01959-3.
- Mahony, M. *et al.* Infective Endocard<sup>\*\*</sup> is in Children in Queensland, Australia: Epidemiology, Clinical Features and Outcome. *P* : *di atr. Infect. Dis. J.* **40**, 617–622 (2021).
- 5. Jortveit, J., Eskedal, L., Klc <sub>2</sub>ν<sub>c</sub> nsky, J., Døhlen, G. & Holmstrøm, H. Prevalence of infective endocarditis in children. *T*<sub>1</sub>*c* 'sκr Nor Laegeforen 1–5 (2019).
- Gupta, S., Sakhuja, A., 1cGrath, E. & Asmar, B. Trends, microbiology, and outcomes of infective endocardit, in children during 2000–2010 in the United States. *Congenit. Heart Dis.* 12, 196–201 (2017).
- Webb, R. *et al.* Infective endocarditis in New Zealand children 1994-2012. *Pediatr. Infect. Dis. J.* 33, 437–442 (2014).
- Sakai Bizmark, R., Chang, R. K. R., Tsugawa, Y., Zangwill, K. M. & Kawachi, I. Impact of AHA's 2007 guideline change on incidence of infective endocarditis in infants and children. *Am. Heart J.* 189, 110–119 (2017).
- Baltimore, R. S. *et al.* Infective endocarditis in childhood: 2015 update A scientific statement from the American Heart Association. *Circulation* 132, 1487–1515 (2015).
- 10. Rushani, D. *et al.* Infective endocarditis in children with congenital heart disease: Cumulative incidence and predictors. *Circulation* **128**, 1412–1419 (2013).

- Rosenthal, L. B. *et al.* The changing epidemiology of pediatric endocarditis at a children's hospital over seven decades. *Pediatr. Cardiol.* **31**, 813–820 (2010).
- Kelchtermans, J. *et al.* Clinical Characteristics of Infective Endocarditis in Children. *Pediatr. Infect. Dis. J.* 38, 453–458 (2019).
- Jortveit, J. *et al.* Endocarditis in children and adolescents with congenital heart defects: a Norwegian nationwide register-based cohort study. *Arch. Dis. Child.* **103**, 670–674 (2018).
- Cao, G. fang & Bi, Q. Pediatric Infective Endocarditis and Stroke: A 13-Year Single-Center Review. *Pediatr. Neurol.* **90**, 56–60 (2019).
- Day, M. D., Gauvreau, K., Shulman, S. & Newburger, J. W. Ciperacteristics of children hospitalized with infective endocarditis. *Circulation* **119**, 865 -876 (2009).
- 16. Weber, R. *et al.* Interventions using foreign material to treat congenital heart disease in children increase the risk for infective endocarditis. *Pediatr. Infect. Dis. J.* **27**, 544–550 (2008).
- 17. Knirsch, W., Schuler, S. K., Martin, C. & Roland, W. L.me-trend population analysis of the clinical and epidemiologic effect on pediatric infuctive endocarditis after change of antibiotic prophylaxis guidelines. *Infection* (2020, α i:10.1007/s15010-020-01433-4.
- Li, J. S. *et al.* Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis. *Clin. Infect. Dis.* **30** (235- 638 (2000).
- Wilson, W. *et al.* Prevention of Infective Endocarditis: Guidelines from the American Heart Association. *Circulation* 11:3, 1726–1754 (2007).
- 20. Flückiger, U. & Jaussi, A. Revidierte schweizerische Richtlinien für die Endokarditis-Prophylaxe. *Kardiovaski läre Medizin* **11**, 392–400 (2008).
- 21. Habib, G. et al. 2015 ESC Guidelines for the management of infective endocarditis. European Heart Journal vol. 36 (2015).
- Knirsch, W., Mackenzie, C. R., Schäfers, H.-J., Baumgartner, H. & Kramer, H.-H. Infektiöse Endokarditis und Enokarditisprophylaxe - Leitlinien der deutschen Gesellschaft für Pädiatrische Kardiologie. (2014).
- Shamszad, P., Khan, M. S., Rossano, J. W. & Fraser, C. D. Early surgical therapy of infective endocarditis in children: A 15-year experience. *J. Thorac. Cardiovasc. Surg.* 146, 506–511 (2013).
- 24. Jomaa, W. *et al.* Clinical features and prognosis of infective endocarditis in children: Insights from a Tunisian multicentre registry Aspects. *Arch. Cardiovasc. Dis.* **110**, 676–681 (2017).
- 25. Esposito, S. et al. Infective Endocarditis in Children in Italy from 2000 to 2015. Expert Rev.

Anti. Infect. Ther. 14, 353–358 (2016).

- 26. Marom, D., Ashkenazi, S., Samra, Z. & Birk, E. Infective endocarditis in previously healthy children with structurally normal hearts. *Pediatr. Cardiol.* **34**, 1415–1421 (2013).
- Elder, R. W. & Baltimore, R. S. The Changing Epidemiology of Pediatric Endocarditis. *Infect. Dis. Clin. North Am.* 29, 513–524 (2015).
- Thom, K. *et al.* Incidence of infective endocarditis and its thromboembolic complications in a pediatric population over 30 years. *Int. J. Cardiol.* 252, 74–79 (2018).
- Sun, L. C. *et al.* Risk factors for infective endocarditis in children with congenital heart diseases
  A nationwide population-based case control study. *Int. J. Ca. iol.* 248, 126–130 (2017).
- Johnson, J. A., Boyce, T. G., Cetta, F., Steckelberg, J. M. & Johr son, J. N. Infective Endocarditis in the Pediatric Patient: A 60-year single-in: titution review. *Mayo Clin. Proc.* 87, 629–635 (2012).
- Khoo, B. *et al.* Outcomes of surgery for infective endocarditis in children: A 30-year experience.
   *J. Thorac. Cardiovasc. Surg.* 158, 1399–1405 (10.9).
- 32. Lalani, T. *et al.* Prosthetic valve endocard is dire to coagulase-negative staphylococci:
   Findings from the International Collaboration on Endocarditis Merged Database. *Eur. J. Clin. Microbiol. Infect. Dis.* 25, 365–36<sup>p</sup> (2006).
- 33. Lin, Y. T., Hsieh, K. S., Chen Y. S., Huang, I. F. & Cheng, M. F. Infective endocarditis in children without underlying hear disease. *J. Microbiol. Immunol. Infect.* **46**, 121–128 (2013).
- 34. Lee, J. H. *et al.* Surgical out comes of infective endocarditis in children: Should we delay surgery for infective endocarditis? *Eur. J. Cardio-thoracic Surg.* **60**, 920–927 (2021).
- 35. Nunes, M. C. P. *et al* Outcomes of infective endocarditis in the current era: Early predictors of a poor prognosis. *Int. J. Infect. Dis.* **68**, 102–107 (2018).
- Mohanan, S. *et al.* Baseline C-reactive protein levels and prognosis in patients with infective endocarditis: A prospective cohort study. *Indian Heart J.* **70**, S43–S49 (2018).
- 37. Cornelissen, C. G., Frechen, D. A., Schreiner, K., Marx, N. & Krüger, S. Inflammatory parameters and prediction of prognosis in infective endocarditis. *BMC Infect. Dis.* **13**, (2013).
- Vicent, L., Luna, R. & Martínez-Sellés, M. Pediatric Infective Endocarditis: A Literature Review.
   *J. Clin. Med.* 11, (2022).
- Sharma, A., Cote, A. T., Hosking, M. C. K. & Harris, K. C. A Systematic Review of Infective Endocarditis in Patients With Bovine Jugular Vein Valves Compared With Other Valve Types. JACC Cardiovasc. Interv. 10, 1449–1458 (2017).

- 40. Jalal, Z. *et al.* Long-term Complications After Transcatheter Atrial Septal Defect Closure: A Review of the Medical Literature. *Can. J. Cardiol.* **32**, 1315.e11 (2016).
- 41. Luca, A. C. *et al.* Difficulties in diagnosis and therapy of infective endocarditis in children and adolescents—cohort study. *Healthc.* **9**, (2021).
- 42. Jacobwitz, M. *et al.* Neurologic complications of infective endocarditis in children. *Cardiol.* Young 1–10 (2022) doi:10.1017/s1047951122001159.
- 43. Cheung, G. *et al.* Infective endocarditis following percutaneous pulmonary valve replacement:
  Diagnostic challenges and application of intra-cardiac echocardiography. *Int. J. Cardiol.* 169, 425–429 (2013).

## 8. Tables

Table 1 Predisposing factors for IE in children.

| Congenital Heart Disease*                                       |          | RV-PA conduit       |
|---|----------|---------------------|
| Cyanotic CHD  | n=32     | n=26                |
| Tetralogy of Fallot (TOF)                                       | n=9      | n=9                 |
| Pulmonary atresia (PA)  | n=7      | n=7                 |
| Double outlet right ventricle (DORV)                            | n=5      | n=3                 |
| Truncus arteriosus communis                                     | n=4      | n=4                 |
| Transposition of the great arteries (TGA)                       | n=3      | n=2                 |
| Hypoplastic left heart syndrome (HLHS)                          | n=2      | n=1                 |
| Double outlet right ventricle with tricuspid atresia (DORV +TA) | n=1      | r =0                |
| Unbalanced AVSD   | n=1      | n≞ Դ                |
| Non-cyanotic CHD  | n=26     | <del>آ=</del>       |
| Ventricular septal defect (VSD)                                 | n }      | n=0                 |
| Bicuspid aortic valve (AV)                                      | n ò      | n=2                 |
| Atrioventricular septal defect (AVSD)                           | n: 4     | n=0                 |
| Aortic valve (AV) stenosis                                      | n=3      | n=2                 |
| Atrial septal defect (ASD)                                      | n=2      | n=0                 |
| Absent pulmonary valve (PV)                                     | n=1      | n=1                 |
| Shone-complex   | n=1      | n=1                 |
| Complete atrioventricular (AV)-block                            | n=1      | n=0                 |
| Other predisposing factors*                                     |          | L                   |
| Central venous line   | n=9 (one | permanent)          |
| Genetic syndromes   | n=5      |                     |
| DiGeorge syndrome   | n=3 (oi  | ne with trisomy 9p) |
| Trisomy 21  | n=1      |                     |
| Right isomerism with asplenia                                   | n=1      |                     |
| Immunodeficiency  | n=4      |                     |
| Hypogammaglobulinemia   | n=2      |                     |
| Autoimmune neutropenia  | n=1      |                     |
| Chronic granulomatous disease                                   | n=1      |                     |
| Oncologic Comorbidities   | n=3      |                     |
| Common ALL  | n=2      |                     |
| Kidney clear cell sarcoma                                       | n=1      |                     |
| Preterm   | n=2      |                     |
| Previous IE   | n=2      |                     |
| No known predisposing factors                                   | n=8      |                     |

\*some patients presented with more than one predisposing factor

#### Table 2 Blood culture findings

|                             | All patients | Foreign material | Non foreign | Unknown      |
|-----------------------------|--------------|------------------|-------------|--------------|
|                             |              | associated IE    | material IE | localization |
|                             | n=69         | n=33 (48%)       | n=20 (29%)  | n=16 (23%)   |
|                             | (100%)       |                  |             |              |
| Staphylococcus spp.         | n=25 (36%)   | n=10 (14%)       | n=11 (16%)  | n=4 (6%)     |
| Staphylococcus aureus       | n=19         | n=7 (10%)        | n=9 (13%)   | n=3 (4%)     |
| Coagulase negative          | (28%)        | n=3 (4%)         | n ≈2 (3%)   | n=1 (1%)     |
| Staphylococcus              | n=6 (9%)     |                  | 0           |              |
| Streptococcus spp.          | n=13 (19%)   | n=6 (9%)         | ri-2 (4%)   | n=4 (6%)     |
| Viridans-Streptococci       | n=10         | n=6 (9%)         | n=0 (0%)    | n=4 (6%)     |
| Non-Viridans-Streptococci   | (14%)        | n=0 (0%)         | n=3 (4%)    | n=0 (0%)     |
|                             | n=3 (4%)     | X                |             |              |
| Enterococci spp.            | n=8 (12%)    | n=2 (3%)         | n=2 (3%)    | n=4 (6%)     |
| HACEK                       | n=6 (9%)     | n=2 (3%          | n=2 (3%)    | n=2 (3%)     |
| Other pathogens             | n=9 (13%)    | r -4 6° ,)       | n=3 (4%)    | n=2 (3%)     |
| Hemophilus influenza Type B | n=2          | n=u              | n=1         | n=1          |
| Granulicatella adiacens     | n=2          | ר=ר<br>          | n=0         | n=1          |
| Abiotrophia defectiva       | n=1          | n=1              | n=0         | n=0          |
| E. coli                     | n=î          | n=1              | n=0         | n=0          |
| Klebsiella oxytoca          | η=,          | n=0              | n=1         | n=0          |
| Serratia marescens          | n=           | n=0              | n=1         | n=0          |
| Candida albicans            | n=1          | n=1              | n=0         | n=0          |
| Blood-culture negative IE   | n=8 (12%)    | n=5 (7%)         | n=3 (4%)    | n=0 (0%)     |

Abbreviations: HACEK = Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella

Table 3 Clinics, complications, therapy and outcome

| Clinical findings                  |            |   |
|------------------------------------|------------|---|
| Fever and / or shivering           | n=66 (96%) |   |
| Decreased general health condition | n=36 (52%) |   |
| New / altered valve function*      | n=29 (42%) |   |
| Aortic valve regurgitation         | n=5        |   |
| Mitral valve regurgitation         | n=10       |   |
| Mitral valve stenosis              | n=1        |   |
| Pulmonary valve regurgitation      | n=4        |   |
| Pulmonary valve stenosis           | n=10       |   |
| Acute obstruction of melody valve  | n=1        | S |
| Tricuspid valve regurgitation      | n=3        |   |
| Tricuspid valve stenosis           | n=1        |   |
| Gastrointestinal symptoms*         | n=24 (35)  |   |
| Nausea and / or vomiting           | n≕ 7       |   |
| Inappetence                        | n= ،0      |   |
| Diarrhea                           | n₌ 13      |   |
| Abdominal pain                     | n=8        |   |
| Respiratory tract infection */**   | n=8 (12%)  |   |
| Cough                              | n=4        |   |
| Dyspnea                            | n=2        |   |
| Rhinitis                           | n=2        |   |
| Sore throat                        | n=2        |   |
| IE specific skin affection*        | n=2 (3%)   |   |
| Osler nodes                        | n=2        |   |
| Splinter hemorrhages               | n=2        |   |
| Janeway lesions                    | n=1        |   |
| Unspecific skin affection*         | n=7 (10%)  |   |
| Maculopapular exanthema            | n=3        |   |
| Petechia                           | n=3        |   |
| Suffusion on left hand             | n=1        |   |
| Other symptoms*                    | n=19 (28%) |   |
| Headache                           | n=11       |   |
| Weight loss                        | n=6        |   |
| Myalgia / arthralgia               | n=5        |   |
| No symptoms                        | n=1 (1%)   |   |
| Severe complications               |            |   |
| Congestive heart failure           | n=16 (23%) |   |
| Sepsis                             | n=17 (25%) |   |
|                                    | 1          | 1 |

| Embolism   | n=19 (28%)                           |
|--|--------------------------------------|
| Lung   | n=11                                 |
| Brain  | n=9                                  |
| Spleen   | n=3                                  |
| Kidney   | n=2                                  |
| Extremities  | n=2                                  |
| Retina   | n=1                                  |
| Death  | n=5 (7%)                             |
| Surgical intervention  |                                      |
| Surgery done   | n=32 (46%)                           |
| Early surgical intervention needed   | 24/32 (75%)                          |
| Interval surgery after diagnosis IE, median days (IQR)                       | 21 (7-41)                            |
| For isolated left heart infections   | 7 (3-20)                             |
| For isolated right heart infections  | 31 (11⊸i4)                           |
| Indication for Surgery**   |                                      |
| Valve regurgitation  | 13 <sup>°</sup> 32 <sub>\</sub> `1%) |
| Valve Stenosis   | 1: /32 (38%)                         |
| Embolism or large valvular vegetations                                       | 10/32 (31%)                          |
| Pseudoaneurysm due to rupture of ventriculo-proste. $\gamma s \upsilon'$ are | 1/32 (3%)                            |
| Change of pacemaker leads  | 1/32 (3%)                            |
| AVSD-direct closure  | 1/32 (3%)                            |
| Loose VSD-patch  | 1/32 (3%)                            |
| Type of surgery****  |                                      |
| Valve replacement  | 15/32 (47%)                          |
| Valve reconstruction   | 12/32 (38%)                          |
| Large vegetation removal   | 9/32 (28%)                           |
| Thrombus removal in right ventri le  | 2/32 (6%)                            |
| VSD-Closure  | 2/32 (6%)                            |
| ASD-Closure  | 1/32 (3%)                            |
| Change of pacemaker leads  | 1/32 (3%)                            |
| Hospitalisation  |                                      |
| Duration of hospitalization, median days (IQR)                               | 42 (23-46)                           |
| Intensive care needed  | n=40 (58%)                           |
|  |                                      |

\* Multiple findings possible

\*\* (without impaired cardiac function)

 $^{\star\star\star}$  some patients fulfilled more than one indication for surgery

\*\*\*\* some patients received more than one type of surgery

| Table 4 Univariate analysis - pre | redictors of severe complications | in children with IE |
|-----------------------------------|-----------------------------------|---------------------|
|-----------------------------------|-----------------------------------|---------------------|

|   | All IE         | By Severe Com       | plications    |       |
|---|----------------|---------------------|---------------|-------|
|   |                |                     |               |       |
|   |                | Present             | Not Present   | p-    |
|   | n=69           | n=35 (51%)          | n=34 (49%)    | value |
|   |                |                     |               |       |
| Age, median years (IQR)                             | 6.39 (0.81 -   | 6.90 (0.6 -         | 5.35 (0.8 -   | 0.50  |
|   | 12.60)         | 14.3)               | 11.4)         |       |
| Male, n total (%)                                   | 42/69 (61%)    | 25/42 (60%)         | 17/42 (40%)   | 0.07  |
| Diagnosis after first symptome, median days (IQR)   | 6.5 (3 - 14)   | 6 (3 – 14)          | 7 (3 – 13)    | 0.90  |
| Risk factors, n total (%)                           | 59/69 (86%)    | 27 " 9 (5 %)        | 32/59 (54%)   | 0.08  |
| Congenital Heart Disease                            | 58/69 (84%)    | <u>ک. 158</u> (46%) | 31/58 (54%)   | 0.19  |
| Cyanotic Heart Disease                              | 32/69 (46%)    | 1: /32 (41%)        | 19/32 (59%)   | 0.12  |
| CHD recommended for antibiotic prophylaxis          | 42/58 (72%)    | 18/42 (43%)         | 24/42 (57%)   | 0.37  |
| Previous IE   | 2/69 (3%)      | 1/2 (50%)           | 1/2 (50%)     | 1     |
| Central venous catheter                             | 9/6? (13%)     | 4/9 (44%)           | 5/9 (56%)     | 0.73  |
| Postoperative IE, n total (%)                       | · 3/6. (7, J%) | 21/48 (44%)         | 27/48 (56%)   | 0.26  |
| Foreign material used                               | 44/4ວ (92%)    | 20/44 (45%)         | 24/44 (55%)   | 0.62  |
| RV-PA conduit                                       | 32/69 (46%)    | 13/32 (41%)         | 19/32 (59%)   | 0.12  |
| Surgery within 30 days before diagnosis             | 9/69 (19%)     | 3/9 (33%)           | 6/9 (67%)     | 0.31  |
| Localization of IE, n total (%)                     |                |                     |               | 0.70  |
| Left Heart  | 15/69 (22%)    | 10/15 (66%)         | 5/15 (33%)    |       |
| Right Heart   | 31/69 (45%)    | 14/31 (45%)         | 17/31 (55%)   |       |
| Other   | 23/69 (33%)    | 11/23 (48%)         | 12/23 (52%)   |       |
| Pathogen found, n total (%)                         |                |                     |               | 0.02  |
| Staphylococcus aureus                               | 19/69 (28%)    | 14/19 (74%)         | 5/19 (26%)    | 0.02  |
| Coagulase negative Staphylococcus                   | 7/69 (10%)     | 5/7 (71%)           | 2/7 (29%)     | 0.43  |
| Streptococcus                                       | 13/69 (19%)    | 5/13 (38%)          | 8/13 (62%)    | 0.33  |
| НАСЕК   | 6/69 (9%)      | 3/6 (50%)           | 3/6 (50%)     | 1     |
| Enterococcus  | 8/69 (12%)     | 5/8 (63%)           | 3/8 (37%)     | 0.71  |
| Clinical course                                     |                |                     |               |       |
| CRP level at admission, median concentration (mg/l) | 75 (32-157.2)  | 101.5 (47-206)      | 55.6 (28-106) | 0.11  |
| (IQR)   |                |                     |               |       |

Abbreviations: CRP = c-reactive protein; HACEK = Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella; RV-PA

= Right-ventricular to pulmonary artery conduit

# 9. Appendix

Table A. Possible transient bacteremia

| Possible transient bacteremia                          | n=29 (42%)                       |
|--|----------------------------------|
| Dental source  | n=8 (12%)                        |
| Carious tooth lesions                                  | n=2                              |
| Dental procedure before diagnosis                      | n=4 (within 2 weeks to 2 months) |
| Gingivitis   | n=1                              |
| Aphthae  | n=1                              |
| Skin source  | n=10 (14%)                       |
| Sternotomy with wound Infection                        | n=1                              |
| Necrotizing fasciitis after Varicella Zoster infection | n=1                              |
| Bacterial superinfection after Herpes Zoster infection | n=1                              |
| Atopic dermatitis with excoriated lesions              | n=1                              |
| Laceration wound                                       | n=1                              |
| Abrasion wound   | n=1                              |
| Panaritium   | n=1                              |
| Cellulitis and folliculitis                            | n 1                              |
| Acne   | 1=1                              |
| Bee sting  | . =1                             |
| Central venous line                                    | n=9 (13%)                        |
| Temporary central venous line                          | n=8                              |
| Permanent central venous line                          | n=1                              |
| Other entry sites                                      | n=2 (3%)                         |
| Infectious sacroiliitis                                | n=1                              |
| Scoliosis correction surgery                           | n=1 (3 days before diagnosis)    |
| Necrotizing enterocolitis                              | n=1                              |

| Table B. Infectious diseases a | associated with manifested IE |
|--------------------------------|-------------------------------|
|--------------------------------|-------------------------------|

| Associated infectious diseases*   | n=14 (20%) |
|---|------------|
|   |            |
| Pneumonia   | n=11       |
|   |            |
| Meningitis  | n=3        |
|   |            |
| Osteomyelitis   | n=1        |
|   |            |
| Epiglottitis  | n=1        |
|   |            |
| Cholecystitis   | n=1        |
|   |            |
| Pyelonephritis  | n=1        |
|   |            |
| Polvarthritis   | n=1        |
|   |            |
| Peritonitis after peritoneal dialysis due to heart-failure associated renal failure | n=1        |
|   |            |
|   |            |

\* Multiple findings possible

| Cardiac findings and complications                          | n=36 (52%)  |  |
|---|-------------|--|
| Symptoms of heart failure*                                  | n=16 (23%)  |  |
| Hemodynamic instability                                     | n=6         |  |
| Pulmonary oedema due to left heart failure                  | n=8         |  |
| Hepatomegaly due to right heart failure                     | n=3         |  |
| Reduced myocardial function in echocardiogram               | n=2         |  |
| Cardiac surgery associated complications                    | n=2 (3%)    |  |
| AV-Block Grade II (Wenckebach) with hemodynamic instability | n=1         |  |
| Pericardial tamponade                                       | n=1         |  |
| Other   | n=1 (1%)    |  |
| Aneurysmatic RV-PA conduit                                  | n=1         |  |
| Extracardiac findings and complications                     |             |  |
| Neurologic complications*                                   | n=11 (1, %) |  |
| Embolism  | n. :9       |  |
| Intracranial bleeding (2x combined with cerebral embolism)  | r =3        |  |
| Status epilepticus  | ı =1        |  |
| Grand mal seizure (complex fever seizure)                   | n=1         |  |
| Renal complications*  | n=20 (29%)  |  |
| Kidney injury / renal failure                               | n=11        |  |
| Glomerulonephritis  | n=15        |  |
| Renal embolism  | n=2         |  |
| Pulmonal complications*                                     | n=18 (26%)  |  |
| ARDS  | n=3         |  |
| Embolism  | n=11        |  |
| Pulmonary oedema  | n=8         |  |
| Pulmonary hemorrhages                                       | n=1         |  |
| Gastrointestinal complications*                             | n=14 (20%)  |  |
| Hepatomegaly due to right heart failure                     | n=3         |  |
| Shock liver   | n=1         |  |
| Splenomegaly  | n=8         |  |
| Splenic embolism  | n=3         |  |
| Hematologic complications*                                  | n=61 (88%)  |  |
| Anemia  | n=58        |  |
| Thrombocytopenia (1x with purpura fulminans)                | n=40        |  |
| Allergic complications                                      | n=2 (3%)    |  |
| Type I allergic reaction to Penicillin                      | n=1         |  |
| Potential Stevens-Johnson-Syndrome due to Vancomycin        | n=1         |  |
| Endocrinological complications                              | n=2 (3%)    |  |

| Table C. Cardiac and extracardiac | findings and | complications |
|-----------------------------------|--------------|---------------|
|-----------------------------------|--------------|---------------|

| Infection-triggered SIADH    | n=1      |
|------------------------------|----------|
| Stress induced hyperglycemia | n=1      |
| Other complications          | n=5 (7%) |
| Rhabdomyolysis               | n=1      |
| Vasculitis                   | n=1      |
| Conjunctival bleeding        | n=1      |
| Retinal embolism             | n=1      |
| Embolism into extremities    | n=1      |

\* Multiple findings possible

\*\* (without impaired cardiac function)

Abbreviations: AV = atrio-ventricular; RV-PA = right ventricular to pulmonary and r; ARDS = acute respiratory distress syndrome; SIADH = syndrome of inadequate ADH-secretion

The second s 

#### Author Agreement Form – International Journal of Cardiology

Manuscript Title: Swiss Evaluation Registry for Pediatric Infective Endocarditis (SERPIE) - Risk factors for complications in children with infective endocarditis

List of all Authors: Schuler Stefanie Katharina , Crisinel Pierre Ale, Joye Raphael, Rohr Marie, Bressieux-Degueldre Sabrina, Glöckler Martin, Paioni Paolo, Agyeman Philipp K. A., Knirsch Walter

Corresponding Author: Walter Knirsch

This statement is to certify that all authors have seen and approved the manuscript being submitted, have contributed significantly to the work, attest to the validity and legitimacy of the data and its interpretation, and agree to its submission to the *International Journal of Cardiology*.

We attest that the article is the Authors' original work, has not received prior publication and is not under consideration for publication elsewhere. We adhere to the statement of ethical publishing as appears in the International of Cardiology (citable as: Shewan LG, Rosano GMC, Henein N°7, Coats AJS. A statement on ethical standards in publishing scientific articles in the International Journal of C. "diology family of journals. Int. J. Cardiol. 170 (2014) 253-254 DOI:10.1016/j.ijcard.2013.11).

On behalf of all Co-Authors, the corresponding Author shall bear full esponsibility for the submission. Any changes to the list of authors, including changes in order, additions removals will require the submission of a new author agreement form approved and signed by all the original and added submitting authors.

All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. If there are no conflicts of interest, the COI should read: "The authors report no relationships t<sup>1</sup> at could be construed as a conflict of interest".

SUN

### Highlights SERPIE-Study

- SERPIE is the first nation-wide registry for pediatric infective endocarditis in Switzerland
- Most patients with pediatric infective endocarditis suffered from a congenital heart disease
- The right ventricular to pulmonary artery outflow tract conduit was mostly infected
- The most common pathogen for infective endocarditis is Staphylococcus aureus
- Staphylococcus aureus is significantly associated with severe complications